KAINOS LABORATORIES, INC. KAINOS Laboratories, Inc. Share Price
Equities
4556
JP3205650009
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,212 JPY | +0.17% |
|
+2.28% | +11.09% |
| Sales 2009 | 3.59B 22.69M 1.89B | Sales 2010 | 4.22B 26.61M 2.22B | Capitalization | 1.4B 8.85M 738M |
|---|---|---|---|---|---|
| Net income 2009 | 168M 1.06M 88.45M | Net income 2010 | 101M 638K 53.18M | EV / Sales 2009 | 0.43 x |
| Net Debt 2009 | 893M 5.64M 470M | Net Debt 2010 | 909M 5.74M 478M | EV / Sales 2010 | 0.55 x |
| P/E ratio 2009 |
3.96
x | P/E ratio 2010 |
13.8
x | Employees | 133 |
| Yield 2009 |
2.68% | Yield 2010 |
2.38% | Free-Float | 38.54% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.17% | ||
| 1 week | +2.28% | ||
| Current month | +1.25% | ||
| 1 month | -0.82% | ||
| 3 months | +1.85% | ||
| 6 months | +18.13% | ||
| Current year | +11.09% |
1 week
1 190.00
1 227.00
1 month
1 160.001 240.00
Current year
1 055.001 289.00
1 year
1 000.001 289.00
3 years
929.001 945.00
5 years
681.002 047.00
10 years
453.002 047.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yukihiro Nagatsu
PSD | President | 64 | 01/82/01 |
Akihiko Suga
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sumio Shirai
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nobuo Nakano
BRD | Director/Board Member | 70 | - |
Yukihiro Nagatsu
PSD | President | 64 | 01/82/01 |
Tsukasa Hayashi
ADM | Chief Administrative Officer | 62 | 01/93/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1,212 | +0.17% | 3,400 |
| 25/24/25 | 1,210 | -0.08% | 16,700 |
| 24/24/24 | 1,211 | +0.58% | 1,900 |
| 23/24/23 | 1,204 | +1.01% | 4,100 |
| 22/24/22 | 1,192 | +0.59% | 2,200 |
Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST
More quotes
KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.
Calendar
09/05/2024
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +11.09% | 34.26M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- 4556 Stock
